Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to $4000.0.

  • Precision Biosciences' Change in Receivables rose 12105.26% to $4000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$184000.0, marking a year-over-year increase of 9443.27%. This contributed to the annual value of -$672000.0 for FY2024, which is 47127.07% down from last year.
  • Per Precision Biosciences' latest filing, its Change in Receivables stood at $4000.0 for Q3 2025, which was up 12105.26% from -$4000.0 recorded in Q2 2025.
  • Precision Biosciences' 5-year Change in Receivables high stood at $9.3 million for Q1 2021, and its period low was -$49.8 million during Q3 2022.
  • In the last 5 years, Precision Biosciences' Change in Receivables had a median value of -$26000.0 in 2023 and averaged -$4.0 million.
  • In the last 5 years, Precision Biosciences' Change in Receivables skyrocketed by 22007.6% in 2021 and then crashed by 5194000.0% in 2023.
  • Over the past 5 years, Precision Biosciences' Change in Receivables (Quarter) stood at -$18.8 million in 2021, then surged by 100.03% to $5000.0 in 2022, then tumbled by 51940.0% to -$2.6 million in 2023, then surged by 101.58% to $41000.0 in 2024, then crashed by 90.24% to $4000.0 in 2025.
  • Its Change in Receivables was $4000.0 in Q3 2025, compared to -$4000.0 in Q2 2025 and -$225000.0 in Q1 2025.